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Drug-Induced Cholestasis
Vinay Sundaram1 and Einar S. Bj€ornsson2,3
Cholestatic drug-induced liver injury (DILI) can be a diagnostic challenge due to a large differential diagnosis, variability in
clinical presentation, and lack of serologic biomarkers associated with this condition. The clinical presentation of drug-
induced cholestasis includes bland cholestasis, cholestatic hepatitis, secondary sclerosing cholangitis, and vanishing bile duct
syndrome. The associate mortality of cholestatic DILI can be as high as 10%, and thus prompt recognition and removal of
the offending agent is of critical importance. Several risk factors have been identiﬁed for drug-induced cholestasis, including
older age, genetic determinants, and properties of certain medications. Antibiotics, particularly amoxicillin/clavulanate, remain
the predominant cause of cholestatic DILI, although a variety of other medications associated with this condition have been
identiﬁed. In this review, we summarize the presentation, clinical approach, risk factors, implicated medications, and manage-
ment of drug-induced cholestatic liver injury. (Hepatology Communications 2017;1:726-735)
Introduction
Drug-induced liver injury (DILI) presents asigniﬁcant burden to the health care sys-tem.(1) Furthermore, recognition of DILI
may be challenging as it is often a diagnosis of exclu-
sion, clinical presentation is variable, there is a paucity
of data available regarding risk factors, and standard-
ized diagnostic testing for this condition does not
exist.(2) In the setting of DILI, there are several pat-
terns of liver enzyme elevation; drug-induced cholesta-
sis can be deﬁned as an increase in alkaline
phosphatase (ALP) greater than 2 times the upper
limit of normal (ULN) and/or an alanine aminotrans-
ferase (ALT)/ALP ratio of less than 2.(3) One can also
differentiate hepatocellular versus cholestatic DILI by
calculating the R value, which uses ALP and ALT lev-
els and is deﬁned as: (ALT/ULN of normal ALT)/
(ALP 3 ULN of normal ALT).(4) When using this
formula, the clinician should use the local laboratory’s
ULN for ALT and ALP.(5) Hepatocellular injury
presents with a predominant elevation of serum ami-
notransferases and an R factor greater than 5, often
before the onset of jaundice, while cholestatic DILI
has a value of less than 2. A mixed liver injury pattern
has characteristics of both cholestatic and hepatocellu-
lar injury, with an ALT/ALP ratio greater than 2 but
less than 5, although mixed injury is often considered
to be a similar entity to cholestatic DILI.(6) Among
these three patterns, cholestatic injury occurs in 20%-
40% of cases.(7)
Drug-induced cholestasis can have several histologic
features. Cholestatic hepatitis is the most common
form of DILI leading to cholestasis.(8,9) Bland chole-
stasis, typically associated with oral contraceptives and
anabolic steroids, is characterized by canalicular dilata-
tion and bile plugs but without signiﬁcant inﬂamma-
tion. Idiosyncratic liver injury can also lead to ductal
injury, including vanishing bile duct syndrome.(8,10,11)
In the majority of cases, liver test abnormalities
reverse with the cessation of the offending drug.(12)
However, the time course for improvement with chole-
static injury is often slower than for hepatocellular
injury.(13,14)
Case
A 46-year old man was seen for evaluation of abnor-
mal liver enzymes, jaundice, and pruritus. He is an
actor who was taking doxycycline for acne for a period
of 3 months prior to presentation. At the time, he was
also taking multiple vitamins and herbal supplements,
including lysine, glycine, arginine, alpha lipoic acid,
chlorophyll, and turmeric also for a 3-month period.
At the time of presentation, his ALT was 817, AST
was 293, and total bilirubin was 10.5 mg/dL. Viral
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hepatitis and autoimmune hepatitis serologies were
negative. A magnetic resonance cholangiogram was
normal without ductal structuring or dilatation. Repeat
enzymes performed 11 days after presentation revealed
an ALT of 177 and AST of 93, but a signiﬁcant rise in
total bilirubin to 25.9 mg/dL. Therefore, a liver biopsy
was performed that demonstrated cholestatic hepatitis
(Fig. 1). The patient was managed with supportive
care, including the use of plasmapharesis to manage
his pruritus. Repeat enzymes at 15 days after presenta-
tion revealed an improvement in total bilirubin to 23.7
mg/dL. Follow-up testing every 2 weeks demonstrated
progressive improvement in the patient’s transaminitis
and hyperbilirubinemia, and at 3 months after presen-
tation his aminotransferase and bilirubin levels were
within normal limits.
Pathophysiology
Hepatic drug transport has been shown to be involved
in the pathophysiology of cholestatic effects from
drugs.(15,16) In the liver, transport at the apical membrane
into hepatocytes involves the organic anion transporting
polypeptide, and inhibition of this efﬂux protein can lead
to cholestasis from certain medications or their metabo-
lites.(15) The movement of drugs into bile involves cana-
licular transporters of the multidrug resistance (MDR)
protein (MRP) family, which includes glycoproteins
MDR1 (ABCB1), MDR3 (ABCB4), MRP2
(ABCC2), and bile salt export pump (BSEP).(15) The
BSEP has been shown to be a major transporter of bile
salts and drug metabolites from hepatocytes into
bile.(15,16) Drugs that inhibit export on the canalicular
side through inhibition of BSEP can lead to cholestasis
in susceptible individuals.(15) For instance, patients with
mutations in genes that encode BSEP or MDR3 have a
3-fold increased risk of cholestatic DILI from oral con-
traceptives, psychotropic drugs, proton pump inhibitors,
and certain antibiotics.(17) Additional molecular mecha-
nisms involved in drug-induced cholestasis include
destruction of the cytoskeleton, impaired trafﬁcking and
disruption of the tight junction network, and inhibition
of adenosine triphosphate-dependent transporters.(18)
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FIG. 1. Central vein with lymphocytic inﬁltration and hepato-
cellular cholestasis, consistent with cholestatic hepatitis.
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Clinical Approach
The clinical presentation of cholestatic DILI is vari-
able, ranging from asymptomatic elevation in ALP to
symptoms of jaundice, pruritus, and fever. Unfortu-
nately, there are no serologic markers that can reliably
diagnose DILI, and therefore a thorough history is
necessary regarding use of prescription and over-the-
counter medications as well as vitamin and herbal sup-
plements, along with the timing of when these prod-
ucts were used.
The most common method to assess causality
between the liver injury and the suspected offending
medication is the Roussel Uclaf assessment model
(RUCAM).(3,19) The RUCAM, published in 1990 by
the Council for International Organizations of Medi-
cal Sciences, is a causality assessment tool that assigns
a score to six domains based on chronologic and clini-
cal criteria.(20,21) The ﬁnal score, ranging from –5 to
14, determines the likelihood of a causal relationship
between the suspected offending drug and liver injury.
Although the RUCAM offers an objective and stan-
dardized assessment of causality regarding DILI, its
reliability has been questioned.(22) However, RUCAM
can be useful in clinical practice as it places focus on
the major determinants that the diagnosis of DILI
should be based on, such as exact exposure time, devel-
opment of liver tests after dechallenge, exclusion of
competing causes, and documented hepatotoxicity of
the implicated agent. The diagnosis of DILI should
ultimately be determined based on these parameters as
well as clinical judgment.
The differential diagnoses for cholestatic DILI is
large, and a discussion regarding the number of condi-
tions with associated cholestatic liver injury is beyond
the scope of this article. Signs or symptoms of infec-
tion should guide toward a more thorough exclusion of
hepatitis that can sometimes show features of cholesta-
sis. Thus, cholestasis can occur with certain viral infec-
tions, such as hepatitis A and E,(23) Epstein-Barr
virus,(24) typhoid fever,(25) and acute Q fever.(26) In
general, drug-induced cholestasis is a rare phenome-
non, with one large case series of over 4,000 patients
evaluated for acute or chronic liver disease demonstrat-
ing cholestatic DILI was the etiology of liver disease in
<1% of patients evaluated.(27) Abdominal pain can
occur as part of drug-induced cholestatic hepatitis,
although if it is the predominant symptom, then an
alternate cause, such as choledocolithiasis and/or ductal
obstruction, should be evaluated with an ultrasound or
cholangiography.(6) In patients with normal
hepatobiliary imaging and long-standing cholestasis,
primary biliary cholangitis (PBC) or autoimmune hep-
atitis with overlap syndrome of PBC should be
assessed by appropriate serologic markers. Bland chole-
stasis can occur in association with sepsis and cardiac
failure.(28) Cases have also reported cholestasis from
secondary sclerosing cholangitis due to large-vessel
vasculitis.(29)
There is no standard guideline regarding when to per-
form a liver biopsy, although this can be considered in the
patient with progressively worsening liver enzymes and
otherwise unremarkable evaluation to rule out diseases,
such as anti-mitochondrial antibody-negative PBC,
small-duct primary sclerosing cholangitis or autoimmune
hepatitis with overlapping features. A liver biopsy can also
differentiate between acute and chronic cholestasis, which
can ultimately have different prognoses.(8)
Risk Factors
CHEMICAL PROPERTIES OF
DRUGS
The chemical properties of certain drugs may pre-
dispose to cholestatic DILI, although notably this
association is not speciﬁc to cholestatic DILI and may
also be associated with hepatocellular injury. The qui-
nolones temaﬂoxacin and trovaﬂoxacin have a diﬂuori-
nated side chain, making them highly lipophilic and
subsequently associated with cholestatic liver dis-
ease.(21) In a study using data from two pharmaceutical
databases in the United States, daily doses of oral med-
ications greater than 50 mg were shown to be signiﬁ-
cantly associated with severe DILI, of which one third
of cases had a cholestatic injury pattern.(30) In another
analysis of approximately 600 patients from the Span-
ish Hepatotoxicity Registry, 77% of patients with
DILI received medications with daily doses greater
than 50 mg, with 50% having a cholestatic or mixed
pattern of liver injury.(14) These ﬁndings suggest that
administration of medications in dosages greater than
50 mg a day may increase the risk of DILI, including
cholestatic DILI. This risk may be further enhanced
with medications that are excreted by the biliary system
compared to drugs with minimal biliary excretion
(74% versus 40%).(31)
AGE
Cholestatic pattern of DILI is more common
among the elderly, whereas hepatocellular
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DILI seems to be more common in younger indi-
viduals,(14,32) with one study demonstrating that 61%
of DILI cases in patients older than 60 years were of a
cholestatic pattern compared to 39% of patients youn-
ger than 60.(14) A mixed pattern was also signiﬁcantly
more common in older patients than younger
patients.(14) The reason for this age-related susceptibil-
ity to cholestatic liver injury is unclear but may be
related to reduced expression of hepatocellular
transporters.(33)
UNDERLYING LIVER DISEASE
In general, it is uncertain whether preexisting liver
disease is a risk factor for the development of DILI. It
is notable, though, that ALT and ALP levels trended
toward being lower in the setting of DILI among those
with underlying hepatitis C virus infection or nonalco-
holic fatty liver disease.(34) However, certain conditions
may increase susceptibility to drug-induced cholestasis.
For instance, in patients with a history of intrahepatic
cholestasis of pregnancy, there appears to be greater
predisposition toward a cholestatic liver injury from
oral contraceptives or postmenopausal hormone
replacement.(35,36) Rifampicin seems to be associated
with an increased risk for hepatotoxicity in patients
with primary biliary cirrhosis.(37,38) There are few data
to support the notion that a previous episode of chole-
stasis predisposes to an increased risk of DILI in the
future. Data from the Spanish Hepatotoxicity Registry
suggest that multiple episodes of DILI associated with
different drugs in the same patient are rare, occurring
only in 9 of 742 patients studied (1.2%).(21)
GENETIC DETERMINANTS
One of the most common medications leading to
cholestatic DILI is
amoxicillin/clavulanate (Augmentin).(6) The associ-
ated human leukocyte antigen (HLA) haplotypes
HLA B1*1501-DRB5*0101-DQB1*0602,149 have
been seen in 57% of patients with amoxicillin/clavula-
nate-induced DILI compared to only 12% of patients
who do not experience DILI when taking this medica-
tion.(39) Data from the Spanish Registry, however, did
not conﬁrm this association but revealed a signiﬁcantly
higher prevalence of the HLA-DQR1*06 allele com-
pared to controls.(40) Those with cholestatic/mixed
DILI from amoxicillin/clavulanate were also found to
have a signiﬁcantly higher frequency of HLA-
DRB1*15 and HLADQB1*06 alleles and a lower fre-
quency of DRB1*07 and DQB1*02 alleles.(40)
Flucloxacillin is a commonly used antibiotic in the
United Kingdom, Australia, Sweden, and some other
countries. In a genome-wide association study of
ﬂucloxacillin-induced DILI, Daly et al.(41) reported an
association in the major histocompatibility complex
region, with the strongest association observed for
rs2395029, a marker in complete linkage disequilib-
rium with HLA-B*5701. Direct genotyping for HLA-
B*5701 in 51 cases and 63 drug-exposed controls
revealed a strong relationship between this allele and
ﬂucloxacillin-induced liver injury (odds ratio 80.6).(41)
Increased susceptibility of cholestatic injury due to oral
contraceptives has a reported association with the T to
C polymorphism in BSEP 1331.(42)
Clinical Patterns
VANISHING BILE DUCT
SYNDROME
Vanishing bile duct syndrome is diagnosed when
less than 50% of bile ducts are seen on biopsy. It is a
rare syndrome considered to occur in only 0.5% of
cases of small duct biliary disease, although it can
potentially cause cirrhosis by leading to near complete
absence of ducts.(43-45) Even though the pathogenesis
of vanishing bile duct syndrome secondary to DILI
has not been fully elucidated, it is thought that an
immunologic response, predominantly from T cells,
leads to recognition of antigen on biliary epithelial
cells, resulting in immune cell inﬁltration into the
intraepithelial layer of the bile ducts, apoptosis, and T-
cell cytotoxicity.(46)
Vanishing bile duct syndrome is seen mainly in
patients with prolonged cholestasis for months or years.
This was most commonly associated with the drug
chlorpromazine,(11) although more than 40 medica-
tions(44,47) have been implicated in vanishing bile duct
syndrome, including amoxicillin,(48) carbamaze-
pine,(49,50) meropenem,(51) and ﬂucloxacillin.(45,48) In a
recent prospective report from the DILI network, 26 of
363 (7%) patients were reported to experience vanishing
bile duct syndrome secondary to drug injury, which pre-
sented most commonly as cholestatic hepatitis.(10) The
most commonly implicated agents were amoxicillin/
clavulanate, temozolomide, herbal products, and azi-
thromycin. Those who developed bile duct loss were
more likely to have chronic liver injury compared to
HEPATOLOGY COMMUNICATIONS, Vol. 1, No. 8, 2017 SUNDARAM AND BJ €ORNSSON
729
those who did not (94% versus 47%; P < 0.001).(10)
The clinical course associated with vanishing bile duct
syndrome is variable, ranging from reversibility and full
liver recovery to prolonged bile duct loss leading to death
from cholestatic cirrhosis.(50,52) In a recent study from
the DILI network cohort, approximately 19% of liver-
related mortality was observed among patients with bile
duct loss, either as the primary or contributing cause of
death.(7) This mortality rate is numerically greater than
the overall 6.2% overall mortality seen in a recently pub-
lished report of 899 patients with DILI, of which half of
the deaths were ultimately liver related, thus underscor-
ing the seriousness of vanishing bile duct syndrome
compared to other presentations of DILI.(34)
SECONDARY SCLEROSING
CHOLANGITIS
Cholestatic DILI from development of secondary scle-
rosing cholangitis has been reported with chemotherapeu-
tic agents,(53,54) and cases have been reported with
ketamine and methimazole.(55-57) Secondary sclerosing
cholangitis associated with the use of docetaxel was
recently reported.(58) A recent study of cholangiographies
among patients with DILI suggested that up to 10% of
DILI cases may have sclerosing cholangitis-like changes
on magnetic resonance cholangio pancreatography.(59)
Recently presented ﬁndings from Ahmad et al.(60) from
the DILI network cohort identiﬁed four cases of drug-
induced secondary sclerosing cholangitis (7%) from a total
of 56 patients with biliary imaging. Of these four cases,
one was from moxiﬂoxacin, one from atorvastatin, and
two from herbal supplements. One of the four case sub-
jects needed liver transplantation.
ACUTE CHOLESTASIS IN DILI
Acute cholestasis from DILI can be categorized into
pure or bland cholestasis, and cholestatic hepatitis,
which is accompanied by inﬂammatory cell inﬁltrate,
degenerative changes, and possible hepatocellular
necrosis.(8) In pure cholestasis, bile plugs are detected
in canaliculi and/or hepatocytes, predominantly zone 3
of the liver parenchyma. Inﬂammation, hepatocytic
degeneration, and necrosis are absent, and no bile duct
damage is seen.(6,23) This pattern of liver injury is com-
monly associated with oral contraceptives, anabolic ste-
roids, warfarin, prochlorperazine, and thiabendazole.(6)
It should be noted that cholestasis from sepsis, cardiac
failure, or after surgery can lead to bland cholestasis
and should be considered in the differential.(28)
In cholestatic hepatitis, bile accumulation in the liver
is accompanied by inﬂammation and hepatocellular
injury. The presence of eosinophils in the inﬂamma-
tory inﬁltrate suggests a better prognosis,(61,62) A num-
ber of medications have been implicated in causing
cholestatic hepatitis. The differential diagnosis
includes but is not limited to acute viral hepatitis, auto-
immune hepatitis, and acute large duct obstruction.(63)
Histologically, cholestatic DILI, whether bland or
with inﬂammation, is predominantly found in zone 3
of the liver.(63,64) A list of agents associated with acute
cholestasis from DILI is presented in Table 1.
CHRONIC CHOLESTASIS IN DILI
Chronic cholestasis is diagnosed when cholestatic
liver injury persists for more than 3 months.(63)
TABLE 1. DRUGS IDENTIFIED AS POTENTIALLY
LEADING TO ACUTE CHOLESTATIC LIVER INJURY
Bland Cholestasis
Oral contraceptives
Anabolic steroids
Warfarin
Thiabendazole
Procholperazine
Cholestatic hepatitis
Cholestatic Hepatitis
Penicillins
Sulfonamides
Fluoroquinolones
Tetracyclines
Antifungals (terbinafine, griseofulvin, ketoconazole, itraconazole)
Antiretroviral therapy (stavudine, didanosine, nevirapine)
Anti-inflammatory (diclofenac, sulindac, piroxicam, ibuprofen,
phenylbutazone, gold, pencilamine, allopurinol, azathioprine)
Psychotropes (chlorpromazine, prochlorperazine, fluphenazine,
thiroridazine, tricyclic antidepressants, risperidone, duloxetine,
benzodiazepines, diazepam)
TABLE 2. DRUGS IDENTIFIED AS POTENTIALLY
LEADING TO CHRONIC CHOLESTATIC LIVER
INJURY
Vanishing Bile Duct Syndrome
Psychotropes (chlorpromazine, imipramine, carbamazepine,
amitriptyline, haloperidol, cyproheptadine, phenytoin)
Antibiotics (amoxicillin/clavulanate, flucloxacillin, quinolones,
clindamycin, macrolides, tetracyclines)
Nonsteroidal anti-inflammatory drugs (diclofenac, ibuprofen)
Others (amiodarone, cimetidine, thiabendazole, zonisamide, ajmaline)
Secondary Sclerosing Cholangitis
Docetaxel
Ketamine
Methimazole
Chemotherapeutic agents
Atorvastatin
Moxifloxacillin
Various herbal supplements
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Medications that have been typically associated with
chronic cholestasis are primarily antibiotics and anti-
fungals, chlorpromazine, ibuprofen, and amiodarone;
rarely oral contraceptives have been associated with
chronic cholestatic DILI(45,65-67) (Table 2). Unfortu-
nately, persistent cholestasis even without inﬂamma-
tion can lead to long-term liver damage due to ductal
sclerosis, periportal ﬁbrosis, and bile duct loss.(6)
Drugs Commonly
Associated With Cholestatic
Liver Injury
Although a comprehensive list of drugs reported to
have induced hepatotoxicity has been published(68) and
can also be found on the website http://www.livertox.
nih.gov, we will describe the most common categories
of medications leading to cholestatic DILI.
ANTIBIOTICS AND
ANTIFUNGALS
In several published reports, antibiotics have been
found to be the most common category of drugs that
lead to cholestasis.(69-71) Speciﬁc examples of antibiot-
ics/antifungals that can lead to cholestatic DILI are
reviewed below.
AMOXICILLIN/CLAVULANATE
This particular antibiotic is among the most com-
mon antibiotics leading to DILI.(32,69) In a study from
the United Kingdom, one third of drug-induced jaun-
dice was associated with amoxicillin/clavulanate.(71) In
the Spanish Hepatotoxicity Registry, amoxicillin/clav-
ulanate was the most common cause of DILI, with 59/
461 (13%) of all DILIs related to amoxicillin/clavula-
nate.(32) In the United States, amoxicillin/clavulanate
was the most common antibiotic associated with
DILI.(70) Liver injury usually develops early in the
course of treatment but also late in the course of pro-
longed treatment and even after discontinuation of
therapy.(72) Liver injury is mainly related to the clavu-
lanic acid component as the incidence of DILI with
amoxicillin/clavulanate is markedly higher than that of
amoxicillin alone.(73) Risk factors for hepatotoxicity are
age greater than 65 years, female sex, and repeated
courses of the antibiotic.(71-73) Most cases are mild,
but protracted courses have been seen, and cases can
rarely lead to acute liver failure or require
transplantation.(72,74,75)
PENICILLINS
Flucloxacillin-induced cholestasis is well docu-
mented.(44,48,76,77) Flucloxacillin is commonly pre-
scribed in the United Kingdom, Sweden, and
Australia, and is the most common reason for idiosyn-
cratic liver injury in Sweden, accounting for 16% of
cases, with 5% of those cases leading to mortality.(12,71)
Female sex, and older age have been shown to have
greater risk of liver injury caused by ﬂucloxacillin.(45,76)
Although often resolving after discontinuation of the
drug, more severe presentations include ductopenia(48)
and cholestatic liver failure.(45,77) Other semisynthetic
penicillinase-resistant penicillins, such as cloxacillin,
dicloxacillins, and oxacillins, have been shown to
induce cholestatic hepatitis.(70,77)
MACROLIDES
Erythromycin may cause a cholestatic liver injury.(78)
Erythromycin was the second most commonly
reported antibiotic to cause DILI in Sweden.(12) In a
collection of case reports, cholestatic injury was
observed in 69% of cases.(61) The prognosis is generally
favorable, and reports of acute liver failure and death
are rare.(61,69) Clarithromycin and azithromycin have
also been associated with cholestatic liver injury.(79-81)
TRIMETHOPRIM/
SULFAMETHOXAZOLE
Trimethoprim/sulfamethoxazole was the fourth most
common antibiotic inducing DILI in North America
according to a study from the DILI network, after
amoxicillin/clavulanate, isoniazid, and nitrofuran-
toin.(69,70) The sulfonamide component is considered to
be responsible for the cholestatic pattern of liver
injury.(82) Almost 60% of reactions are of a cholestatic
nature.(61) Approximately 10% of case subjects with cho-
lestatic jaundice caused by trimethoprim/sulfamethoxa-
zole either died or underwent liver transplantation.(12)
TETRACYCLINES
With low-dose tetracyclines, such as doxycycline,
the incidence seems to be lower compared to other
antibiotics leading to DILI.(83,84) Liver injury induced
by tetracyclines can be cholestatic, hepatocellular, or
mixed pattern, with similar frequencies.(83)
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OTHER ANTI-INFECTIOUS
MEDICATIONS
The antifungal terbinaﬁne can cause a cholestatic
injury that can be potentially life-threatening.(85,86)
Terbinaﬁne-induced hepatotoxicity has been reported
in several patients from large series from Sweden and
the United States.(12,70) Quinolones that can also lead
to cholestatic hepatitis(87) include ciproﬂoxacin(86,88)
and levoﬂoxacin, which have in fact been linked to
vanishing bile duct syndrome.(89)
DILI caused by cephalosporins has previously been
considered to be extremely rare. However, a recent
study from the DILI network in the United States
described 33 cases of 1,212 patients enrolled between
2004 and 2012.(90) Most patients had a cholestatic
liver injury pattern, and in several cases the toxicity
occurred after therapy had been stopped, with two
fatalities.(90)
PSYCHOTROPIC DRUGS
Cholestatic-type injury caused by chlorpromazine is
well documented and leads to cholestatic hepatitis,
ductopenia, and cholestatic cirrhosis.(11) Cholestatic
hepatitis has also been reported after tricyclic antide-
pressants, such as imipramine and amitryptiline,(4) and
the serotonin re-uptake inhibitor duloxetine.(91)
ANTI-INFLAMMATORY DRUGS
Azathioprine, a commonly used immunomodulator,
has been reported to cause potentially fatal cases of
cholestatic hepatitis.(92-94) Most patients develop liver
injury during the ﬁrst 3 months of therapy.(95) The fre-
quency of azathioprine-induced DILI ranges from 3%
according to data from a retrospective study(96) to as
high as 10% based on a prospective study.(95) Diclofe-
nac, a commonly used nonsteroidal anti-inﬂammatory
drug, is mostly associated with a hepatocellular pattern
of liver injury,(95) although cholestatic reactions associ-
ated with diclofenac have also been reported.(97)
Ibuprofen-induced vanishing bile duct syndrome lead-
ing to cirrhosis has been reported in a previously
healthy child.(98) Nimesulide is almost exclusively
hepatocellular.
ORAL CONTRACEPTIVES
The long-term use of oral contraceptives has been
associated with an increased risk of several different
presentations of liver injury, including intrahepatic
canalicular cholestasis.(36,99) However, cholestatic and
hepatocellular liver enzyme elevations are equally fre-
quent from low-dose estrogen oral contraceptives. The
range of time between treatment and the onset of liver
injury can range from 3 to 360 days, with a median
time of 60 days.(100)
TREATMENT
There is no medical therapy for the treatment of
cholestatic DILI. Instead, treatment involves with-
drawal of the suspected drug, avoiding drug rechal-
lenge, and treatment of symptoms.(6) Cessation of the
offending drug is imperative if the patient develops
severe injury as evidenced by jaundice or elevation of
serum aminotransferases to greater than 3 times the
ULN, known as Hy’s law.(101)
Ursodeoxycholic acid may be prescribed, but the
data in cholestatic DILI are largely lacking. The major
beneﬁt from ursodeoxycholic acid in cholestatic liver
disease in general is protection against cytotoxicity
caused by toxic bile salts, stimulation of hepatobiliary
secretion, antioxidant activity, enhancement in gluta-
thione levels, and the inhibition of liver cell apopto-
sis.(102) Management of pruritus secondary to severe
cholestasis includes the use of cholestyramine, antihist-
amines, rifampin, phenobarbital, and opioid analogues,
which can be used to ameliorate pruritus. Ultraviolet B
phototherapy and plasmapharesis are alternative treat-
ments in those who have failed medical therapy.(28)
Conclusion
Drug-induced cholestasis can result in acute or
chronic liver injury. Most cases of cholestatic DILI
appear to resolve shortly after drug withdrawal, but a
subset of cases can progress to chronic cholestasis, cir-
rhosis, and subsequent hepatic decompensation. Early
recognition and prompt withdrawal of the offending
drug is the mainstay of initial management. This
review summarizes the implicated drugs, diagnostic
tools, and management of drug-induced cholestasis.
Proper reporting of adverse drug reactions and out-
comes are important as new drugs are being developed
and approved.
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